Article
Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.
Cancer medicine - 1 Feb 2022
Katayama Yuki, Yamada Tadaaki, Tokuda Shinsaku, Okura Naoko, Nishioka Naoya, Morimoto Kenji, Tanimura Keiko, Morimoto Yoshie, Iwasaku Masahiro, Horinaka Mano, Sakai Toshiyuki, Kita Kenji, Yano Seiji, Takayama Koichi
Abstract excerpt
EGFR-T790M mutation is a major mechanism underlying acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) in lung cancer with mutated EGFR. However, differences in the biological characteristics of T790M tumors based on treatment regimens with each generation of EGFR-TKI are not fully understood. We established cell lines with acquired resistance harboring EGFR-T790M...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.